Replies to post #241842 on Biotech Values

[randychub]

I bought a bit at the open. Those results look promising. Hoping adding Opdivo (nivolumab) improves these outcomes.

[Bickema]

is there any hope for CLVS at these levels? I know their financials are a mess. Either more dilution needed, a partnership, or a buyout needed last time i checked.

[DewDiligence]

CLVS -31% on negative FDA feedback re Rubraca-monotherapy data in ovarian cancer first-line maintenance setting:

https://endpts.com/that-big-rd-parp-win-clovis-ceo-mahaffy-touted-a-few-weeks-ago-the-fda-isnt-buying-it/

The problem is the FDA isn’t being won over on PFS data, according to Clovis. They want mature OS data — and we find that the agency specified at least 50% mature OS data — which Clovis estimates won’t be available for another 2 years…

I can’t find this information in a CLVS PR or SEC filing, so I presume it came out in some other form.